- Home
- SHO vs ETNB Comparison
SHO vs ETNB Comparison
Compare SHO & ETNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SHO
- ETNB
- Stock Information
- Founded
- SHO 1995
- ETNB 2018
- Country
- SHO United States
- ETNB United States
- Employees
- SHO N/A
- ETNB N/A
- Industry
- SHO Hotels/Resorts
- ETNB Biotechnology: Pharmaceutical Preparations
- Sector
- SHO Consumer Discretionary
- ETNB Health Care
- Exchange
- SHO Nasdaq
- ETNB Nasdaq
- Market Cap
- SHO 1.7B
- ETNB 1.5B
- IPO Year
- SHO 1995
- ETNB 2019
- Fundamental
- Price
- SHO $8.69
- ETNB $10.08
- Analyst Decision
- SHO Hold
- ETNB Strong Buy
- Analyst Count
- SHO 6
- ETNB 8
- Target Price
- SHO $10.00
- ETNB $26.43
- AVG Volume (30 Days)
- SHO 2.5M
- ETNB 2.2M
- Earning Date
- SHO 08-06-2025
- ETNB 08-04-2025
- Dividend Yield
- SHO 4.13%
- ETNB N/A
- EPS Growth
- SHO N/A
- ETNB N/A
- EPS
- SHO 0.10
- ETNB N/A
- Revenue
- SHO $922,708,000.00
- ETNB N/A
- Revenue This Year
- SHO $7.98
- ETNB N/A
- Revenue Next Year
- SHO $3.67
- ETNB N/A
- P/E Ratio
- SHO $88.84
- ETNB N/A
- Revenue Growth
- SHO N/A
- ETNB N/A
- 52 Week Low
- SHO $7.45
- ETNB $4.16
- 52 Week High
- SHO $12.41
- ETNB $11.84
- Technical
- Relative Strength Index (RSI)
- SHO 47.27
- ETNB 57.88
- Support Level
- SHO $8.43
- ETNB $9.66
- Resistance Level
- SHO $8.90
- ETNB $10.58
- Average True Range (ATR)
- SHO 0.25
- ETNB 0.55
- MACD
- SHO -0.03
- ETNB -0.09
- Stochastic Oscillator
- SHO 28.57
- ETNB 58.39
About SHO Sunstone Hotel Investors Inc. Sunstone Hotel Investors Inc.
Sunstone Hotel Investors Inc is a real estate investment trust that acquires, owns, manages, and renovates the full-service hotel and select-service hotel properties across various states in the United States. Its firm's portfolio consists upper upscale and luxury hotels located in convention, resort destination and urban markets. Its majority of the hotels operate under a brand owned by Marriott, Hilton, Hyatt, Four Seasons or Montage. It operates geographically in Califiornia which generates the majority of its revenue; Florida; and Hawaii. The company's sole source of income is hotel revenue from its hotel ownership segment.
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).